Triumvira Immunologics Raises $55M in Series A Funding Round

Ontario Industry Updates
Written By Guest User
triumvira-car-t-logo.png

Triumvira Immunologics announced a $55 million Series A round co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i). Triumvira will use the funding to run clinical trials of cell therapies that are directed by an alternative to CARs.

Guest User
Previous

7D Surgical Completes Largest Financing Round to Date
Next

Mobio Interactive Secures $1.8M USD in Seed Funding